1467083-70-0

Basic information

• Product Name: N-(3-bromo-5-fluorobenzyl) methanesulfonamide
• Synonyms: N-(3-bromo-5-fluorobenzyl) methanesulfonamide
• CAS NO: 1467083-70-0
• Molecular Weight: 282.133
• Mol File: 1467083-70-0.mol
• Article Data: 31

Chemical Properties

• CAS DataBase Reference: N-(3-bromo-5-fluorobenzyl) methanesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(3-bromo-5-fluorobenzyl) methanesulfonamide(1467083-70-0)
• EPA Substance Registry System: N-(3-bromo-5-fluorobenzyl) methanesulfonamide(1467083-70-0)

Safety Data

• Hazardous Substances Data: 1467083-70-0(Hazardous Substances Data)

Upstream product

• 1094555-68-6 (3-bromo-5-fluoro-phenyl)methanamine 
• 7143-01-3 Methanesulfonic anhydride 
• 124-63-0 methanesulfonyl chloride 
• 179898-34-1 3-bromo-5-fluorobenzonitrile 
• 188813-02-7 3-bromo-5-fluorobenzaldehyde 
• 3144-09-0 methanesulfonamide 

Downstream Products

• 1467083-71-1 N-(3-(4,5-diaminopyridin-3-yl)-5-fluorobenzyl)methanesulfonamide 

Relevant articles and documents

STRAD-BINDING AGENTS AND USES THEREOF

Disclosed herein, inter alia, are compounds for binding STRAD pseudokinase and uses thereof.

3-(1H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF

4-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of a 4-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF

4-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of a 4-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.